ATRC

Over the past six months, AtriCure's stock experienced an overall decline, reaching a new 52-week low. In Q1 2026, AtriCure reported revenue of $141.25 million, up 14.3% year-over-year, surpassing analyst expectations, and reported $0.00 EPS, beating analysts' consensus estimates. AtriCure reported its fourth-quarter and full-year 2025 financial results around February 17, 2026. Analyst sentiment remains mostly constructive, with a "Moderate Buy" consensus rating. An insider, Vinayak Doraiswamy, sold 5,000 shares of the stock. AtriCure participated in the Citizens Life Sciences Conference in February 2026 and was scheduled to participate in the 2026 Bank of America Securities Health Care Conference in May 2026.